CAS-ViewAlert

View Alert




Originator:		MHRA Drug Alerts
From:		Himal Makwana
Issue date:		25-Oct-2019 12:06:06
This alert has been issued to:
		NHS Regional Offices NHS Foundation Trusts (England) - Medical Director NHS Trusts (England) - Medical Director Territorial CMOs in Northern Ireland, Scotland & Wales Regional Directors of Public Health
		MHRA (Medicines) Drug Alerts (Various Recipients) Other contacts Independent Healthcare Providers (registered with CAS) Clinical Commissioning Groups NHS Foundation Trusts (England) - Chief Executive MHRA (Medicines) Drug Alerts - Non-NHS Recipients Director of Public Health NHS Trusts (England) - Chief Executive GP - Locum GP Practices DHSC Supply Disruption - Medicines
Action category:		Class 2: Action within 48 hours
Title:		CLASS 2 DRUG ALERT, ACTION WITHIN 48 HOURS, ROSEMONT PHARMACEUTICALS LIMITED, RANITIDINE 150MG/10ML ORAL SOLUTION
Broadcast content:		Rosemont Pharmaceuticals Limited is recalling all unexpired stock of Ranitidine 150mg/10ml Oral Solution from pharmacies as a precautionary measure due to possible contamination with an impurity N-nitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential. This alert is the first alert, out of two, related to ranitidine products issued today (25 October 2019) Full details of the drug alert are included in the attached PDF file. Please forward to listed recipients. This information is also published on the MHRA website https://www.gov.uk/drug-device-alerts.
Additional information:		GP Practices: Please share this alert withing your practice to assist the management of patients who use these medicines. NHS England Regional Offices: Please cascade this alert to community pharmacies.
Alert reference:		EL (19)A/29
Attachments:		EL (19)A 29 FINAL.pdf
Cascade to:		#COMMUNITYPHARMACISTS# #DISPENSING GP# #HospitalPharmacy# #GP#